Vertex Pharmaceuticals (MA) (VRTX) Announces A Signed Letter Of Intent To Enable Public Reimbursement Of KALYDECO® (Ivacaftor) In Canada For Eligible People With Cystic Fibrosis
6/17/2014 11:37:38 AM
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has signed a letter of intent with the pan-Canadian Pricing Alliance (pCPA) to enable the public reimbursement of KALYDECO® (ivacaftor) for the treatment of eligible Canadians with cystic fibrosis (CF) ages 6 and older who have the G551D mutation. The letter of intent represents an agreement in principle with the pCPA regarding the public reimbursement of KALYDECO in Canada. However, before patients can get access through public reimbursement, each participating province or territory must decide to reimburse KALYDECO through its individual drug program. In Canada, there are approximately 100 people ages 6 and older with this specific mutation. KALYDECO is the first medicine to treat the underlying cause of cystic fibrosis for people with the G551D mutation in the CFTR gene.
Help employers find you! Check out all the jobs and post your resume.
comments powered by